- Home
- BIIB vs VLTO Comparison
BIIB vs VLTO Comparison
Compare BIIB & VLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- VLTO
- Stock Information
- Founded
- BIIB 1978
- VLTO 2023
- Country
- BIIB United States
- VLTO United States
- Employees
- BIIB N/A
- VLTO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- VLTO Electrical Products
- Sector
- BIIB Health Care
- VLTO Industrials
- Exchange
- BIIB Nasdaq
- VLTO Nasdaq
- Market Cap
- BIIB 25.1B
- VLTO 25.5B
- IPO Year
- BIIB 1991
- VLTO N/A
- Fundamental
- Price
- BIIB $149.53
- VLTO $103.26
- Analyst Decision
- BIIB Buy
- VLTO Buy
- Analyst Count
- BIIB 26
- VLTO 12
- Target Price
- BIIB $248.00
- VLTO $109.50
- AVG Volume (30 Days)
- BIIB 1.6M
- VLTO 1.3M
- Earning Date
- BIIB 02-11-2025
- VLTO 02-04-2025
- Dividend Yield
- BIIB N/A
- VLTO 0.43%
- EPS Growth
- BIIB 10.05
- VLTO N/A
- EPS
- BIIB 11.06
- VLTO 3.24
- Revenue
- BIIB $9,607,500,000.00
- VLTO $5,136,000,000.00
- Revenue This Year
- BIIB N/A
- VLTO $5.56
- Revenue Next Year
- BIIB N/A
- VLTO $5.75
- P/E Ratio
- BIIB $13.47
- VLTO $31.94
- Revenue Growth
- BIIB N/A
- VLTO 3.11
- 52 Week Low
- BIIB $145.07
- VLTO $73.91
- 52 Week High
- BIIB $268.30
- VLTO $115.00
- Technical
- Relative Strength Index (RSI)
- BIIB 31.81
- VLTO 43.80
- Support Level
- BIIB $145.07
- VLTO $100.00
- Resistance Level
- BIIB $149.92
- VLTO $104.54
- Average True Range (ATR)
- BIIB 3.57
- VLTO 1.94
- MACD
- BIIB 0.18
- VLTO -0.19
- Stochastic Oscillator
- BIIB 22.27
- VLTO 44.14
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About VLTO Veralto Corp
Veralto Corp is company which is a provider of essential technology solutions that safeguard many of the world's most vital resources. The company operates in two segments such as Water Quality and Product Quality & Innovation. Through WQ segment it improves the quality and reliability of water through leading brands including Hach, Trojan Technologies and ChemTreat. Through PQI segment it promotes consumer trust in products and help enable product innovation through brands including Videojet, Linx, Esko, X-Rite and Pantone.